Vivos Therapeutics, Inc.

Good day everyone and welcome to the Vivos Therapeutics Incorporated first quarter 2022 earnings call. At this time all participants are in listen-only mode. A question and answer session will follow management's remarks. This conference call is being recorded and a replay of today's call will be available on the investor relations section of Vivos website and will remain posted there for the next 30 days. I will now hand the call over to Julie Gannon, Vivos Investor Relations Officer for introductions and the reading of the Safe Harbor Statement. Please go ahead.

Thank you, Operator. Hello, everyone, and welcome to Devos Therapeutics' first quarter 2022 earnings conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.devos.com. With us on today's call are Kirk Huntsman, Devos Chairman and Chief Executive Officer, and Brad Ammon, Chief Financial Officer. Today we'll review the highlights and financial results for the first quarter of 2022, as well as more recent developments. Following these formal remarks, we will be prepared to answer your questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934 as amended concerning future events. Words such as aim, may, could, should, project, expect, intends, plans, believes, anticipates, hopes, estimates, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond the company's control. Actual results, including without limitation, the results of Vivos growth strategies, operational plans, future potential results of operations or operating metrics, and other matters to be addressed by Vivos management in this conference call may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described and other disclosures contained in vivo filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31, 2021, and our first quarter 2022 Form 10-Q, both of which are or will be accessible on the investor relations section of the VEVOS website, as well as the SEC's website. Except to the extent required by law, VEVOS assumes no obligation to update statements as circumstances change. Finally, the FDA has given certain VEVOS appliances 510 clearance to treat mild to moderate OSA. Any reference herein regarding vivos treatment or the vivos method should be viewed in that context. Treatment of patients with severe OSA are performed off-label at the sole clinical discretion of the treating doctor and are not part of the vivos treatment protocol. Now at this time, it is my pleasure to introduce Kirk Huntsman, Chairman and CEO of vivos. Kirk, please go ahead.

Thank you, Julie. Today we're, excuse me, Today we're going to do things a little differently than our past earnings calls. There are a lot of positive and exciting things happening here at Vivos that merit more time and elaboration than we might normally be able to provide. So I'm going to ask our CFO, Brad Ammon, to quickly run through our first quarter financial numbers so we can get that out of the way and leave time for what we consider to be the deeper story happening here. Brad, if you would please take the floor and present our financial and operating results for the first quarter of 2022.